Overview
Availability
- Associate Professor David Wyld is:
- Available for supervision
Works
Search Professor David Wyld’s works on UQ eSpace
2025
Journal Article
Peptide receptor radionuclide therapy in malignant insulinoma
Pattison, David A., Kong, Grace, Akhurst, Timothy, Burge, Matthew, Chiang, Cherie, Hofman, Michael S., Hung, Te-Jui, Love, Amanda, Michael, Michael, Okano, Satomi, Ravi Kumar, Aravind S., Sachithanandan, Nirupa, Wyld, David and Hicks, Rodney J. (2025). Peptide receptor radionuclide therapy in malignant insulinoma. Endocrine-Related Cancer, 32 (6) e250018, 6. doi: 10.1530/erc-25-0018
2025
Journal Article
Factors that influence clinical trial participation for oncology patients in Australia: a scoping review
You, Kyung Ha, Lwin, Zarnie, Ahern, Elizabeth, Wyld, David and Roberts, Natasha (2025). Factors that influence clinical trial participation for oncology patients in Australia: a scoping review. BMJ Open, 15 (6) e095355, e095355-6. doi: 10.1136/bmjopen-2024-095355
2025
Conference Publication
Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET: A randomized study of cessation of somatostatin analogues (SSA) after peptide receptor radionuclide therapy (PRRT) in mid, hind-gut, and pancreatic neuroendocrine tumours
Burge, Matthew E., Wyld, David, Pattison, David A., Bahamad, Sandra, Hayes, Sarah J., Kuszewski, Julia A., Chantrill, Lorraine A., Price, Timothy Jay, Wong, Hui-Li, Chan, David, Grover, Piyush, Michael, Michael, Siu, Derrick, Bishop, Christine, Barker, Daniel, Goodwin, Rachel Anne, O'Callaghan, Christopher J., Loree, Jonathan M. and Mak, W. John (2025). Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET: A randomized study of cessation of somatostatin analogues (SSA) after peptide receptor radionuclide therapy (PRRT) in mid, hind-gut, and pancreatic neuroendocrine tumours. 2025 ASCO Annual Meeting, Chicago, IL United States, 30 May - 3 June 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.16_suppl.tps4224
2025
Journal Article
Institutional factors associated with equitable cancer care provision for culturally and linguistically diverse populations in Queensland, Australia: a critical race theory analysis
Scanlon, Brighid, Roberts, Natasha, Wyld, David, Toloo, Ghasem Sam and Durham, Jo (2025). Institutional factors associated with equitable cancer care provision for culturally and linguistically diverse populations in Queensland, Australia: a critical race theory analysis. Journal of Racial and Ethnic Health Disparities, 1-15. doi: 10.1007/s40615-025-02477-8
2025
Conference Publication
An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs)
Mak, Blossom, Tran, Ben, Thomas, Hayley, Pashankar, Farzana D., Hansen, Aaron Richard, Feldman, Darren R., Huddart, Robert A, Wheater, Matthew, Dunwoodie, Elaine, Mazhar, Danish, Lawrence, Nicola Jane, Stevanovic, Amanda Gwendolyn, Birtle, Alison Jane, Oladipo, Olabode, Wyld, David, Balagtas, Jay Michael S., Stockler, Martin R., Grimison, Peter S. and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs). 2025 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 13-15 February 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.5_suppl.tps653
2025
Conference Publication
Phase Ib/IIa dose escalation and expansion study of [ <sup>212</sup> Pb]Pb-ADVC001 in metastatic castration-resistant prostate cancer: TheraPb–phase I/II study
Hansen, Aaron Richard, Pattison, David A., Ngai, Stanley, Karmann, Anna, Walker, Amanda J., Campbell, Louise, Brady, Jasmine, Katchel, Loren, Holmes, Ingrid, Rose, Stephen E., Baronet, Meghan C., Kryza, Thomas, Vito, Alyssa, Tieu, William, Kuan, Kevin, Griffiths, Matthew R., O’Mahoney, Eoin, Latter, Melissa, Gan, Chun Loo Loo and Wyld, David (2025). Phase Ib/IIa dose escalation and expansion study of [ 212 Pb]Pb-ADVC001 in metastatic castration-resistant prostate cancer: TheraPb–phase I/II study. 2025 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 13-15 February 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.5_suppl.tps275
2024
Conference Publication
When good intentions are not enough: the development of the Equity ProcEss frameworK (EPEK) to promote equity in cancer
Scanlon, Brighid, Wyld, David, Durham, Jo, Toloo, Sam and Roberts, Natasha (2024). When good intentions are not enough: the development of the Equity ProcEss frameworK (EPEK) to promote equity in cancer. COSA's 51st Annual Scientific Meeting Bridging gaps, building progress, breaking down disparities, Gold Coast, QLD, Australia, 13 - 15 November 2024. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.14116
2024
Journal Article
Patient Reported Outcome Measures in cancer care: a hybrid effectiveness-Implementation trial to optimise Symptom control and health service Experience (PROMISE)–protocol for a randomised controlled trial of electronic self-reporting of symptoms versus usual care during and following treatment in patients with cancer
Webb, Penelope M, Brown, Amy, Brown, Bena, Collins, Louisa G, Crawford Williams, Fiona, Doupain, Kerrie, Eastgate, Melissa, Fennelly, Vicki, Girgis, Afaf, Hartel, Gunter, Ladwa, Rahul, Martin, Karen, Mason, Robert, McGuire, Peter, Miller, Elizabeth, O’Brien, Suzanne, Packer, Rebecca, Pinkham, Mark B, Sabesan, Sabe, Sanmugarajah, Jasotha, Slapp, Georgia, Tapsall, Doreen, White, Jeanie, Wishart, Laurelie R, Wyld, David and Chan, Raymond J (2024). Patient Reported Outcome Measures in cancer care: a hybrid effectiveness-Implementation trial to optimise Symptom control and health service Experience (PROMISE)–protocol for a randomised controlled trial of electronic self-reporting of symptoms versus usual care during and following treatment in patients with cancer. BMJ Open, 14 (11) e090836, 1-10. doi: 10.1136/bmjopen-2024-090836
2024
Conference Publication
"Signing up for the PRoCESS [Pancreatic cancer Relatives Counselling and Education Support Service] Trial was the most important thing I did as a carer"
Beesley, Vanessa L., Roset, Natalie, Turner, Jane, Yates, Patsy, Wyld, David, Eastgate, Melissa, Chan, Raymond, Collins, Louisa, Stewart, Michelle, Beebe, Hanna, Malt, Maryrose, Kelly, Caroline and Neale, Rachel (2024). "Signing up for the PRoCESS [Pancreatic cancer Relatives Counselling and Education Support Service] Trial was the most important thing I did as a carer". COSA's 51st Annual Scientific Meeting: Bridging gaps, building progress, breaking down disparities, Gold Coast, QLD, Australia, 13 - 15 November 2024. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.14116
2024
Conference Publication
Patient reported measures as the optimal assessment of chemotherapy-induced peripheral neuropathy
Li, Tiffany, Timmins, Hannah C., Mahfouz, Fawaz M., Trinh, Terry, Mizrahi, David, Horvath, Lisa G., Harrison, Michelle, Grimison, Peter, Friedlander, Michael, Marx, Gavin, Boyle, Frances, Wyld, David, Henderson, Robert, King, Tracy, Baron-Hay, Sally, Kiernan, Matthew C., Rutherford, Claudia, Goldstein, David and Park, Susanna B. (2024). Patient reported measures as the optimal assessment of chemotherapy-induced peripheral neuropathy. COSA's 51st Annual Scientific Meeting Bridging gaps, building progress, breaking down disparities, Gold Coast, QLD, Australia, 13 - 15 November 2024. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.14116
2024
Conference Publication
Clinical risk factors associated with development of significant nerve damage during chemotherapy
Li, Tiffany, Timmins, Hannah C., Horvath, Lisa G., Harrison, Michelle, Grimison, Peter, Friedlander, Michael, Marx, Gavin, Boyle, Frances, Wyld, David, Henderson, Robert, Baron-Hay, Sally, Kiernan, Matthew C., Barnes, Elizabeth H., Goldstein, David and Park, Susanna B. (2024). Clinical risk factors associated with development of significant nerve damage during chemotherapy. COSA's 51st Annual Scientific Meeting Bridging gaps, building progress, breaking down disparities, Gold Coast, QLD, Australia, 13 - 15 November 2024. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.14117
2024
Journal Article
Implementation of Patient-Reported Outcomes in a Medical Oncology Setting (the iPROMOS Study): type II hybrid implementation study
Roberts, Natasha Anne, Pelecanos, Anita, Alexander, Kimberly, Wyld, David and Janda, Monika (2024). Implementation of Patient-Reported Outcomes in a Medical Oncology Setting (the iPROMOS Study): type II hybrid implementation study. Journal of Medical Internet Research, 26 e55841, e55841. doi: 10.2196/55841
2024
Journal Article
Validity of patient-reported outcome measures in evaluating nerve damage following chemotherapy
Li, Tiffany, Timmins, Hannah C., Mahfouz, Fawaz M., Trinh, Terry, Mizrahi, David, Horvath, Lisa G., Harrison, Michelle, Grimison, Peter, Friedlander, Michael, Marx, Gavin, Boyle, Frances, Wyld, David, Henderson, Robert, King, Tracy, Baron-Hay, Sally, Kiernan, Matthew C., Rutherford, Claudia, Goldstein, David and Park, Susanna B. (2024). Validity of patient-reported outcome measures in evaluating nerve damage following chemotherapy. JAMA Network Open, 7 (8) e2424139, e2424139. doi: 10.1001/jamanetworkopen.2024.24139
2024
Conference Publication
Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trial
Nalder, Mark, Kulasegaran, Tivya, Lundie, Ben, Woods, Rick, Eastgate, Melissa A., Wyld, David and Burge, Matthew E. (2024). Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trial. 2024 ASCO Annual Meeting, Chicago, IL, United States, 31 May–4 June 2024. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2024.42.16_suppl.12121
2024
Conference Publication
Identifying optimized assessment of nerve damage during chemotherapy
Li, Tiffany, Timmins, Hannah C, Mahfouz, Fawaz Mayez, Mizrahi, David, Horvath, Lisa, Harrison, Michelle L., Grimison, Peter S., Friedlander, Michael, Marx, Gavin M., Boyle, Frances M., Wyld, David, Henderson, Robert, King, Tracy, Baron-Hay, Sally E., Kiernan, Matthew C, Rutherford, Claudia, Goldstein, David and Park, Susanna B (2024). Identifying optimized assessment of nerve damage during chemotherapy. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.12016
2024
Journal Article
Corrigendum to: COVID-19 vaccine hesitancy, acceptance and informational needs in an Australian cancer population: a cross-sectional survey
Scanlon, Brighid, Wyld, David, Firman, Paul, Nakagaki, Midori, Durham, Jo, Kennedy, Glen, Moran, Paul, Smith, Michael, Button, Elise and Gavin, Nicole (2024). Corrigendum to: COVID-19 vaccine hesitancy, acceptance and informational needs in an Australian cancer population: a cross-sectional survey. Australian Health Review, 48 (3). doi: 10.1071/ah22142_co
2024
Journal Article
Exploring unmet needs in prostate cancer care: a cross-sectional descriptive study
Roberts, Natasha A., Esler, Rachel, Pearce, Adam, Wyld, David, Smith, Michael, Woollett, Kaylene, Mazariego, Carolyn and Roberts, Matthew J. (2024). Exploring unmet needs in prostate cancer care: a cross-sectional descriptive study. European Urology Open Science, 62, 36-42. doi: 10.1016/j.euros.2024.01.018
2024
Conference Publication
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours (GCTs)
Mak, Blossom, Tran, Ben, Pashankar, Farzana D., Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Feldman, Darren R., Dunwoodie, Elaine, Lawrence, Nicola Jane, Birtle, Alison Jane, Wyld, David, Stevanovic, Amanda Gwendolyn, Balagtas, Jay Michael S., Stockler, Martin R., Davis, Ian D. and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2024). P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours (GCTs). 2024 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 25-27 January 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.4_suppl.tps524
2023
Journal Article
Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRI
Arnfield, Evyn G., Tam, Laura, Pattison, David A., Younger, John, Chikatamarla, Venkata Avinash, Wyld, David, Burge, Matthew, McCormack, Louise, Ladwa, Rahul and Ramsay, Stuart (2023). Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRI. Journal of Nuclear Cardiology, 30 (6), 2676-2691. doi: 10.1007/s12350-023-03345-w
2023
Journal Article
The unmet needs of pancreatic cancer carers are associated with anxiety and depression in patients and carers
Huynh, Thi N. T., Hartel, Gunter, Janda, Monika, Wyld, David, Merrett, Neil, Gooden, Helen, Neale, Rachel E. and Beesley, Vanessa L. (2023). The unmet needs of pancreatic cancer carers are associated with anxiety and depression in patients and carers. Cancers, 15 (22) 5307, 1-12. doi: 10.3390/cancers15225307
Supervision
Availability
- Associate Professor David Wyld is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Completed supervision
-
2020
Master Philosophy
Predictors of dosimetry and outcome to peptide receptor radionuclide therapy in metastatic neuroendocrine tumour.
Principal Advisor
Other advisors: Associate Professor David Pattison
-
2021
Doctor Philosophy
Targeting receptor activator of NF-kB pathways in combination immunotherapy
Associate Advisor
Media
Enquiries
For media enquiries about Associate Professor David Wyld's areas of expertise, story ideas and help finding experts, contact our Media team: